Scientists present that lecanemab clears amyloid plaques by partaking microglia by its Fc fragment, defining the mobile program behind its therapeutic impact Lecanemab, marketed as Leqembi, is a monoclonal antibody therapy for Alzheimer’s illness that reduces the buildup of poisonous amyloid plaques within the mind and slows cognitive decline. Scientists from VIB and KU Leuven […]
Source link
What You Ought to Know The Partnerships: Enterprise AI platform Abridge has secured multi-year content material partnerships with the NEJM Group (writer of the New England Journal of...
Read more










